Drug data last refreshed 16h ago · AI intelligence enriched 4w ago
MESTINON (pyridostigmine bromide) is an oral acetylcholinesterase inhibitor approved in 1959 for treating myasthenia gravis and related neuromuscular conditions. It works by preventing the breakdown of acetylcholine, thereby improving muscle strength and function in patients with compromised neuromuscular transmission. The extended-release tablet formulation provides prolonged symptom control.
Long-established product nearing loss of exclusivity with moderate competitive pressure (45/100), indicating a transition phase requiring strategic repositioning and potential resource reallocation.
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Testing Mestinon and Exercise in Fibromyalgia
Working on MESTINON offers experience in mature product management and competitive defense in a stable therapeutic area. Career value lies in commercial strategy, market access execution, and navigating the transition to generic competition rather than in novel therapeutic development.
Worked on MESTINON at Bausch + Lomb? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.